Evidence map›Paper›PMID 30918081›Full record

ArticleJournal of virology2019

Glucosylceramidase Maintains Influenza Virus Infection by Regulating Endocytosis.

Kelly Drews, Michael P Calgi, William Casey Harrison, Camille M Drews, Pedro Costa-Pinheiro, Jeremy Joseph Porter Shaw, Kendra A Jobe, Elizabeth A Nelson, John D Han, Todd Fox and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Therapeutic Potential of Ceramide in Cancer Treatment.Journal of cancer research and oncobiology · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Genome Editing Tools for Lysosomal Storage Disorders.Advances in experimental medicine and biology · 2023
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Kelly DrewsDepartment of Pathology, University of Virginia, Charlottesville, Virginia, USA.
Michael P Calgi *Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
William Casey Harrison *Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
Camille M DrewsDepartment of Pathology, University of Virginia, Charlottesville, Virginia, USA.
Pedro Costa-PinheiroDepartment of Pathology, University of Virginia, Charlottesville, Virginia, USA.
Jeremy Joseph Porter ShawDepartment of Pathology, University of Virginia, Charlottesville, Virginia, USA.
Kendra A JobeDepartment of Environmental Sciences, University of Virginia, Charlottesville, Virginia, USA.
Elizabeth A NelsonDepartment of Cell Biology, University of Virginia, Charlottesville, Virginia, USA.
John D HanDepartment of Biology, University of Virginia, Charlottesville, Virginia, USA.
Todd FoxDepartment of Pharmacology, University of Virginia, Charlottesville, Virginia, USA.
Judith M WhiteDepartment of Cell Biology, University of Virginia, Charlottesville, Virginia, USA jw7g@virginia.edu mk5vq@virginia.edu.ORCID 0000-0002-0532-996X
Mark KesterDepartment of Pathology, University of Virginia, Charlottesville, Virginia, USA jw7g@virginia.edu mk5vq@virginia.edu.
University of Virginia · US

Funding

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
BIOTECHNOLOGY TRAINING PROGRAMT32GM008715 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LAURIE, GORDON WILLIAM · 2000 to 2019
$6.6M
Combinations of Approved Drugs to Combat Ebola VirusR01AI114776 · NIAID · UNIVERSITY OF VIRGINIA · PI WHITE, JUDITH M. · 2015 to 2017
$1.5M
NCI NIH HHS T32 CA009109NIAID NIH HHS R01 AI114776NIGMS NIH HHS T32 GM008715
6 · The paper itself

Abstract

Influenza virus is an RNA virus encapsulated in a lipid bilayer derived from the host cell plasma membrane. Previous studies showed that influenza virus infection depends on cellular lipids, including the sphingolipids sphingomyelin and sphingosine. Here we examined the role of a third sphingolipid, glucosylceramide, in influenza virus infection following clustered regularly interspaced short palindromic repeats with Cas9 (CRISPR-Cas9)-mediated knockout (KO) of its metabolizing enzyme glucosylceramidase (GBA). After confirming GBA knockout of HEK 293 and A549 cells by both Western blotting and lipid mass spectrometry, we observed diminished infection in both KO cell lines by a PR8 (H1N1) green fluorescent protein (GFP) reporter virus. We further showed that the reduction in infection correlated with impaired influenza virus trafficking to late endosomes and hence with fusion and entry. To examine whether GBA is required for other enveloped viruses, we compared the results seen with entry mediated by the glycoproteins of Ebola virus, influenza virus, vesicular stomatitis virus (VSV), and measles virus in GBA knockout cells. Entry inhibition was relatively robust for Ebola virus and influenza virus, modest for VSV, and mild for measles virus, suggesting a greater role for viruses that enter cells by fusing with late endosomes. As the virus studies suggested a general role for GBA along the endocytic pathway, we tested that hypothesis and found that trafficking of epidermal growth factor (EGF) to late endosomes and degradation of its receptor were impaired in GBA knockout cells. Collectively, our findings suggest that GBA is critically important for endocytic trafficking of viruses as well as of cellular cargos, including growth factor receptors. Modulation of glucosylceramide levels may therefore represent a novel accompaniment to strategies to antagonize "late-penetrating" viruses, including influenza virus.

Indexed as

A549 CellsEbolavirusEndocytosisEndosomesEpidermal Growth FactorErbB ReceptorsGlucosylceramidaseHEK293 CellsHumansInfluenza A virusInfluenza A Virus, H1N1 SubtypeMeasles virusOrthomyxoviridaeVirus InternalizationEpidermal Growth FactorErbB ReceptorsGlucosylceramidaseendocytosisglycolipidsinfluenzavesicular traffickingvirologyvirus entry

Identifiers

PMID30918081
PMCPMC6613767
OpenAlexW2927875593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.